Dr. Bruix Discusses the Success of Regorafenib in HCC
Jordi Bruix, MD
Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the recent success of regorafenib (Stivarga) in hepatocellular carcinoma (HCC) and its impact on the field.
Since sorafenib (Nexavar) was approved for treatment of patients with advanced HCC in 2007, there has been little to no success in trials of second-line treatments.
RESOURCE, a phase III randomized study of regorafenib in the second-line setting, showed a very significant improvement in survival. Bruix, the lead author of the study, says that these results have lifted the morale of the field from its previously discouraged state.